Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA

Next Previous
Trial Profile

A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications Lipohypertrophy
  • Focus Adverse reactions
  • Sponsors Theratechnologies

Most Recent Events

  • 10 Sep 2018 Status changed from active, no longer recruiting to discontinued.
  • 01 Jun 2018 Planned End Date changed from 1 Mar 2030 to 1 Jul 2018.
  • 01 Jun 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top